Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sell transaction in company stock. On May 1, 2026, she exercised 27,000 stock options at an exercise price of $5.20 per share, acquiring the same number of common shares.
That day she made two open-market sales totaling 27,000 common shares: 1,100 shares at a weighted average price of $21.9964 per share and 25,900 shares at a weighted average price of $21.1931 per share. According to a footnote, these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.
Tango Therapeutics, Inc.’s Chief Financial Officer Matthew Gall received new equity-based compensation. He was granted 40,000 shares of Common Stock in the form of restricted stock units, which represent rights to receive an equal number of shares as they vest over time.
The RSUs vest over three years: 13,200 units on or about May 10, 2027, 13,200 on or about May 10, 2028, and 13,600 on or about May 9, 2029, subject to continued service. He was also granted stock options for 240,000 shares of Common Stock at an exercise price of $20.98 per share, vesting 25% on April 15, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, also contingent on continued service.
Tango Therapeutics ownership update: This Amendment No. 2 to a Schedule 13G/A reports that Invus Public Equities directly holds 4,964,650 shares of common stock (approximately 3.5%) and Avicenna Life Sci Master Fund directly holds 692,455 shares (approximately 0.5%), each as of March 31, 2026.
The filing states calculations use 142,688,851 shares outstanding as of February 26, 2026. It discloses control relationships among Invus entities and that Raymond Debbane may be deemed to beneficially own 5,657,105 shares (about 4.0%) through related entities.
Tango Therapeutics director Lee Sung received new equity awards as part of board compensation. On April 29, 2026, Sung was granted 12,300 restricted stock units, each representing one share of common stock. These RSUs vest in three equal annual installments on January 2, 2027, January 2, 2028, and January 2, 2029, contingent on continued board service.
Sung was also granted an option for 5,200 shares of common stock at an exercise price of $22.06 per share. This option vests in 36 substantially equal monthly installments over three years starting January 2, 2026, subject to continued service. Following the grants, Sung holds 22,300 shares of common stock directly and 5,200 stock options, reflecting routine non-employee director compensation rather than open-market trading.
TNGX affiliate submitted a Form 144 notifying an intended sale of 65,460 common shares on 05/01/2026 arising from an exercise of stock options for cash. The filing also reports multiple prior 10b5-1 sales by Adam Crystal totaling reported share lots and proceeds in early 2026.
Tango Therapeutics, Inc. Principal Accounting Officer Jessica Newcomb filed an initial ownership report showing she directly holds 67,321 shares of Common Stock, including 43,666 unvested restricted stock units. She also holds multiple stock options to buy Common Stock at exercise prices between $2.67 and $12.28, expiring between 2032 and 2036, many of which vest over four-year service-based schedules.
Tango Therapeutics, Inc. filed an initial Form 3 for Chief Financial Officer Matthew Gall. The filing identifies him as an officer but, in the provided data, shows no reportable transactions, derivative positions, or other holdings, indicating this is a baseline ownership statement rather than a trading disclosure.
Tango Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026 at 9:00 a.m. Eastern Time. Investors will elect three Class II directors to terms ending in 2029, ratify PricewaterhouseCoopers LLP as auditor for 2026, and give an advisory vote on executive pay.
The proxy also highlights clinical progress, including positive 2025 Phase 1/2 monotherapy data for vopimetostat, initiation of combination studies in MTAP-deleted, RAS-mutant cancers, first dosing with brain-penetrant PRMT5 inhibitor TNG456, and a $225 million financing completed in October 2025. There were 144,242,271 common shares outstanding and entitled to vote as of April 7, 2026.
Tango Therapeutics, Inc. President of R&D Crystal Adam exercised stock options to acquire 38,460 shares of common stock at an exercise price of $5.20 per share, then sold 38,460 shares in an open-market transaction at $25.00 per share. Following the sale, she directly holds 112,622 common shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.